Published in Cancer Weekly, May 17th, 1999
D. Samland and colleagues from the University Magdeburg, Germany, evaluated the long-term clinical effects of a combination therapy with recombinant interleukin-2 (rIL-2), recombinant interferon-alpha(2) (rIFN-alpha(2)) and 5-fluorouracil (5-FU) in patients with advanced metastatic renal cell carcinoma (RCC) seen at a single institution ("Results of Immunochemotherapy with Interleukin-2, Interferon-Alpha(2) and 9-Fluorouracil in the Treatment of Metastatic Renal Cell Cancer," European Urology, March 1999;35(3):204-209).
"From August 1992...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.